Safety and effectiveness of peficitinib 100 mg/day in patients achieving clinical remission from a long-term open-label extension study in Japan, Korea, and Taiwan (RAJ2).
Yoshiya TanakaTsutomu TakeuchiYoshiaki MoritaYuichiro KanekoWataru TeradaPublished in: Modern rheumatology (2024)
Long-term peficitinib treatment at a dose of 100 mg/day was generally well tolerated and, following induction therapy, maintained effectiveness through to W48.
Keyphrases
- end stage renal disease
- randomized controlled trial
- open label
- systematic review
- ejection fraction
- chronic kidney disease
- newly diagnosed
- clinical trial
- peritoneal dialysis
- study protocol
- stem cells
- radiation therapy
- patient reported outcomes
- mesenchymal stem cells
- bone marrow
- phase ii study
- replacement therapy
- phase ii
- smoking cessation
- phase iii
- cell therapy